Published in J Natl Cancer Inst on September 06, 2006
Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med (2011) 1.23
Estrogen receptor mediates a distinct mitochondrial unfolded protein response. J Cell Sci (2011) 1.11
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther (2009) 1.07
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist (2012) 0.90
Prolactin promotes hepatocellular carcinoma through Janus kinase 2. World J Surg (2012) 0.88
Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNA. Oligonucleotides (2009) 0.88
Role of STAT3 in in vitro transformation triggered by TRK oncogenes. PLoS One (2010) 0.82
Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Mol Cancer Ther (2015) 0.80
Extracts of Opuntia humifusa Fruits Inhibit the Growth of AGS Human Gastric Adenocarcinoma Cells. Prev Nutr Food Sci (2016) 0.75
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 4.46
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Mechanisms of action of arsenic trioxide. Cancer Res (2002) 3.68
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest (2009) 2.79
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2004) 2.67
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood (2007) 2.58
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem (2003) 2.44
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A (2009) 2.34
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet (2013) 2.21
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res (2006) 1.97
Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol (2009) 1.95
Retracted A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst (2008) 1.84
Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res (2005) 1.82
Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer. Thorax (2010) 1.80
CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res (2009) 1.80
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal (2014) 1.79
Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res (2007) 1.78
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest. J Cell Sci (2002) 1.75
Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res (2009) 1.72
Retracted The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene. Hum Gene Ther (2009) 1.70
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A (2005) 1.67
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res (2011) 1.62
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) (2011) 1.61
Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res (2004) 1.57
Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene (2005) 1.57
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood (2008) 1.53
KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci Transl Med (2013) 1.53
Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem (2004) 1.53
Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res (2006) 1.52
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood (2005) 1.51
Smc5/6 is required for repair at collapsed replication forks. Mol Cell Biol (2006) 1.51
Coordination of DNA damage responses via the Smc5/Smc6 complex. Mol Cell Biol (2004) 1.49
Endocytosis and degradative sorting of NMDA receptors by conserved membrane-proximal signals. J Neurosci (2004) 1.44
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int (2011) 1.41
Recovery from DNA damage checkpoint arrest by PP1-mediated inhibition of Chk1. EMBO J (2004) 1.38
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood (2003) 1.38
Fission yeast Rnf4 homologs are required for DNA repair. J Biol Chem (2007) 1.37
Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci (2008) 1.36
The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem (2003) 1.32
Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease Omi. J Biol Chem (2008) 1.30
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget (2011) 1.26
Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res (2003) 1.25
Smc5/6 maintains stalled replication forks in a recombination-competent conformation. EMBO J (2009) 1.23
SirT3 regulates the mitochondrial unfolded protein response. Mol Cell Biol (2013) 1.23
Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A (2004) 1.22
Brc1-mediated DNA repair and damage tolerance. Genetics (2005) 1.18
Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis (2011) 1.17
Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3. Mol Cell Biol (2003) 1.17
Regulation of checkpoint kinases through dynamic interaction with Crb2. EMBO J (2004) 1.15
The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol Ther (2009) 1.14
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther (2008) 1.13
Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res (2008) 1.13
Regulation of chk1. Cell Div (2009) 1.12
Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol (2010) 1.12
Estrogen receptor mediates a distinct mitochondrial unfolded protein response. J Cell Sci (2011) 1.11
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther (2002) 1.11
Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res (2006) 1.10
STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol Cell Biol (2013) 1.09
Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet (2011) 1.09
Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene (2005) 1.09
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther (2014) 1.09
Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry (2006) 1.08
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer (2012) 1.05
DNA damage checkpoint maintenance through sustained Chk1 activity. J Cell Sci (2004) 1.05
Smc5-Smc6-dependent removal of cohesin from mitotic chromosomes. Mol Cell Biol (2009) 1.04
A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-gamma in human cancer cells. Cancer Res (2007) 1.04
Autocrine prolactin induced by the Pten-Akt pathway is required for lactation initiation and provides a direct link between the Akt and Stat5 pathways. Genes Dev (2012) 1.04
Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol (2013) 1.04
Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther (2004) 1.03
Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol (2006) 1.03
Regulation of Chk1 by its C-terminal domain. Mol Biol Cell (2008) 1.03
Phosphoinositides regulate P2X4 ATP-gated channels through direct interactions. J Neurosci (2008) 1.03
D3 dopamine autoreceptors do not activate G-protein-gated inwardly rectifying potassium channel currents in substantia nigra dopamine neurons. J Neurosci (2003) 1.02
Protein kinase A modulates PLC-dependent regulation and PIP2-sensitivity of K+ channels. Channels (Austin) (2007) 1.01
DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. Blood (2007) 1.01
Targeting transcription factors: promising new strategies for cancer therapy. Curr Opin Oncol (2013) 1.00
STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1. Blood (2003) 1.00
The fission yeast NIMA kinase Fin1p is required for spindle function and nuclear envelope integrity. EMBO J (2002) 1.00
Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol Ther (2007) 0.99
Normal p53 function in primary cells deficient for Siah genes. Mol Cell Biol (2002) 0.99
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res (2003) 0.99